

DAFTAR PUSTAKA

1. Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. *J Cereb Blood Flow Metab.* 2016;36(3):513-538. doi:10.1177/0271678X15617172
2. Michinaga S, Koyama Y. Pathogenesis of brain edema and investigation into anti-edema drugs. *Int J Mol Sci.* 2015;16(5):9949-9975. doi:10.3390/ijms16059949
3. M. Nehring, Sara.; Prasanna, Tadi.; Tenny S. *Cerebral Edema.*; 2019. <https://www.ncbi.nlm.nih.gov/books/NBK537272/>
4. Shamsaei, Nabi.; Erfani, Soheila.; Fereidoni, Masoud.; Shahbazi A. Neuroprotective Effects of Exercise on Brain Edema and Neurological Movement Disorders Following the Cerebral Ischemia and Reperfusion in Rats. *Basic Clin Neurosci.* Published online 2017:77-84.
5. Dostovic, Zikrija; Dostovic E. Brain Edema After Ischaemic Stroke. *Med Arch.*:70(5): 339-341. doi:10.5455/medarh.2016.70.339-341
6. Balitbang Kemenkes RI. Riset Kesehatan Dasar 2018. Riset Kesehatan Dasar. Jakarta; 2018.
7. Grossman OJMSA. Acute Myocardial Infarction. In: ; 2019.
8. Ghani L, Mihardja LK, Delima D. Faktor risiko dominan penderita stroke di indonesia. *Bul Penelit Kesehat.* 2016;44(1):49-58.
9. Wilder J, Sabatine MS, Lilly LS. Sindroma Koroner Akut. In : Lilly LS. Patofisiologi penyakit jantung : kolaborasi mahasiswa dan dosen; alih bahasa Denio A. Ridjab; editor edisi Bahasa Indonesia, Dafisah A. Juzar. Edisi 6. Jakarta: Penerbit Buku Kedokteran.
10. Kamel H. Cardioembolic Stroke. *Circulation Research.* 2017;120:514–526. doi:10.1161/CIRCRESAHA.116.308407
11. Shah, Ami; Gandhi D. Heart Failure: A Class Review of Pharmacotherapy. *PharmD.*:42(7): 464-472.
12. Mesghali E, Fitter S, Bahjri K, Moussavi K. Safety of Peripheral Line Administration of 3% Hypertonic Saline and Mannitol in the Emergency Department. *J Emerg Med.* 2019 Apr;56(4):431-436.
13. Scheen AJ. [From atherosclerosis to atherothrombosis : from a silent chronic pathology to an acute critical event]. *Rev Med Liege.* 2018 May; 73 (5-6):224-228.
14. Massberg S, Polzin A. [Update ESC-Guideline 2017: Dual Antiplatelet Therapy]. *Dtsch. Med. Wochenschr.* 2018 Aug; 143 (15):1090-1093.
15. Nascimento BR, Brant LCC, Marino BCA, Passaglia LG, Ribeiro ALP. Implementing myocardial infarction systems of care in low/middle-income countries. *Heart.* 2019 Jan; 105 (1):20-26.
16. Neulinger K, Oram J, Tinson H, O’Gorman J, Shum DH. Prospective memory and frontal lobe function. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn.* 2016; 23 (2):171-83.
17. Berlucchi G, Vallar G. The history of the neurophysiology and neurology of the parietal lobe. *Handb Clin Neurol.* 2018; 151 :3-30.
18. Clark RE. Current Topics Regarding the Function of the Medial Temporal Lobe Memory System. *Curr Top Behav Neurosci.* 2018; 37 :13-42.

19. Huff T, Mahabadi N, Tadi P. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Oct 5, 2019. Neuroanatomy, Visual Cortex.
20. Chandra A. The cerebral circulation and cerebrovascular disease I: Anatomy. *Brain Circ* . 2017 Apr-Jun; 3(2): 45–56. doi:10.4103/bc.bc_10_17
21. Rahaman P, Del Bigio MR. Histology of Brain Trauma and Hypoxia-Ischemia. *Acad Forensic Pathol*. 2018;8(3):539-554. doi:10.1177/1925362118797728
22. Hayman EG. Mechanisms of global cerebral edema formation in aneurysmal subarachnoid hemorrhage. doi:10.1007/s12028-016-0354-7
23. Jha RM. Pathophysiology and Treatment of Cerebral Edema in Traumatic Brain Injury. *Neuropharmacology*. doi:10.1016/j.neuropharm.2018.08.004
24. Goriely A. Mechanics of the brain: perspectives, challenges, and opportunities. *Biomech Model Mechanobiol*. doi:10.1007/s10237-015-0662-4
25. Daneman R. The Blood-Brain Barrier. *Cold Spring Harb Perspect Biol*. doi:10.1101/cshperspect.a020412
26. Shah S. The Modern Approach to Treating Brain Swelling in the Neuro ICU. *Semin Neurol*. 2016 Dec; 36(6): 502–507. doi:10.1055/s-0036-1592109
27. Dias C. Optimal Cerebral Perfusion Pressure Management at Bedside: A Single-Center Pilot Study. *Neurocrit Care*. doi:10.1007/s12028-014-0103-8
28. Widyaningsih W, Sugiyanto, Widyarini S, Pramono S. Isoproterenol sebagai model infark miokardial akut pada tikus wistar. 2015;20.
29. Kaplan A, Yabluchanskiy A, Ghali R, Altara R, Booz GW, Zouein FA. Cerebral blood flow alteration following acute myocardial infarction in mice. *Biosci Rep*. 2018;38(5):0–3.
30. Armstead WM. Cerebral Blood Flow Autoregulation and Dysautoregulation. *Anesth Clin*. doi:10.1016/j.anclin.2016.04.002
31. Armstead WM. Preferential Protection of Cerebral Autoregulation and Reduction of Hippocampal Necrosis with Norepinephrine after Traumatic Brain Injury in Female Piglets. *Pediatr Crit Care Med*. doi:10.1097/PCC.0000000000000603
32. Mount CA. Cerebral Perfusion Pressure. Published online 2020.
33. Szymanski, Michael W; Singh DP. Isoproterenol.
34. Biazi GR, Frasson IG, Miksza DR, de Morais H, de Fatima Silva F, Bertolini GL, de Souza HM. Decreased hepatic response to glucagon, adrenergic agonists, and cAMP in glycogenolysis, gluconeogenesis, and glycolysis in tumor-bearing rats. *J. Cell. Biochem*. 2.
35. Eltobshy SA. Effects of heme oxygenase-1 upregulation on isoproterenol-induced myocardial infarction. *Korean J Physiol Pharmacol*. doi:10.4196/kjpp.2019.23.3.203
36. Wang J. Chlorogenic acid prevents isoproterenol-induced DNA damage in vascular smooth muscle cells. *Mol Med Rep*. doi:10.3892/mmr.2016.5743
37. Zhou Z. The Astrocytic cAMP Pathway in Health and Disease. *Int J Mol Sci*. doi:10.3390/ijms20030779
38. Van Diepen S, Katz JN, Albert NM, Henry TD, Jacobs AK, Kapur NK, Kilic A, Menon V, Ohman EM, Sweitzer NK, Thiele H, Washam JB, Cohen MG., American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Q.

39. Khalil MI. Amelioration of Isoproterenol-Induced Oxidative Damage in Rat Myocardium by *Withania somnifera* Leaf Extract. *Biomed Res Int*. doi:10.1155/2015/624159
40. Gunawan SG. Farmakologi dan terapi. 6th ed. Jakarta: Badan Penerbit FK UI; 2016. 345–365 p.
41. Williams B. Drug discovery in renin-angiotensin system intervention: past and future. *Ther Adv Cardiovasc Dis*. 2016 Jun;10(3):118-25.
42. Patel S, Rauf A, Khan H, Abu-Izneid T. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies. *Biomed. Pharmacother*. 2017 Oct;94:317-325.
43. Cozma A. Pharmacogenetic Implications of eNOS Polymorphisms (Glu298Asp, T786C, 4b/4a) in Cardiovascular Drug Therapy. *In Vivo (Brooklyn)*. doi:10.21873/invivo.11573
44. Chen Z. The role of nitric oxide in stroke. *Med Gas Res*. doi:10.4103/2045-9912.215750
45. Zhang Y, Ding X, Hua B, Liu Q, Chen H, Zhao XQ, Li W, Li H. Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome. 2020 Apr .
46. Silvariño R, Rios P, Baldovinos G, Chichet MA, Perg N, Sola L, Saona G, De Souza N, Lamadrid V, Gadola L. Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used? *Nephron*. 2019; 143 (2): 100-107.
47. Desimine VL, McCrink KA, Parker BM, Wertz SL, Maning J, Lymperopoulos A. Biased Agonism/Antagonism of Cardiovascular GPCRs for Heart Failure Therapy. *Int Rev Cell Mol Biol*. 2018; 339 :41-61.

